

REFERÈNCIES

1. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. *Neuron* Jan; 25 (1):239-52.
2. Ahmed MU, Brinkmann Frye E, Degenhardt TP, Thorpe SR, Baynes JW (1997) N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. *Biochem J.* Jun 1;324 (Pt 2):565-70.
3. Ahmed N, Battah S, Karachalias N, Babaei-Jadidi R, Horanyi M, Baroti K, Hollan S, Thornalley PJ (2003) Increased formation of methylglyoxal and protein glycation, oxidation and nitrosation in triosephosphate isomerase deficiency. *Biochim Biophys Acta.* Oct 15;1639(2):121-32.
4. Ahn BH, Rhim H, Kim SY, Sung YM, Lee MY, Choi JY, Wolozin B, Chang JS, Lee YH, Kwon TK, Chung KC, Yoon SH, Hahn SJ, Kim MS, Jo YH, Min DS (2002) α -synuclein interacts with phospholipase D isozymes and inhibits pervadante-induced phospholipase D activation in human embryonic kidney-293 cells. *J Biol Chem* 277: 12334-12342.
5. Alam ZI, Daniel Se, Lee AJ, Marsden CD, Jenner P, Halliwell B (1997) A generalized increase in protein carbonyls in the brain in Parkinson but not in incidental Lewy body disease. *J Neurochem* 69:1326-9.
6. Alam ZI, Jenner A, Daniel Se, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B (1997) Oxidative DNA damage in the Parkinsonian brain: an apparent selective increase in 8-hydroxyquanine levels in substantia nigra. *J Neurochem* 69:1196-203.
7. Albasanz JL, Leon D, Ruiz MA, Fernandez M, Martin M (2002) Adenosine A1 receptor agonist treatment up-regulates rat brain metabotropic glutamate receptors. *Biochim Biophys Acta* 1593: 69-75.
8. Alim MA, Hossain MS, Arima K, Takeda K, Izumiyama Y, Nakamura M, Kaji H, Shinoda T, Hisanaga S, Ueda K. (2002) Tubulin seeds alpha-synuclein fibril formation. *J Biol Chem.* Jan 18;277(3):2112-7
9. Alvard EC Jr, Forno LS, Kusske JA, Kauffman RJ, Rhodes JS, Goetowski CR (1974) The pathology of Parkinsonism: a comparison of degenerations in cerebral cortex and brainstem. *Adv Neurol* 5:175-193.
10. Arima K, Ueda K, Sunohara N, Arakawa K, Hirai S, Nakamura M, Tonzuka-Uehara H, Kawai M. (1998) NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. *Acta Neuropathol (Berl).* Nov;96(5):439-44.
11. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. (2002) Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. *Science* Feb 1; 295 (5556):865-8. Epub 2001 Dec 20.
12. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. *Am J Pathol* 152:879-884.
13. Ballard C, McKeith I, Burn D, Harrison R, O'Brien J, Lowery K, Campbell M, Perry R, Ince P (1997) The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies. *Acta Neurol Scand* 96:366-371.
14. Ballard C, McKeith I, Harrison R, O'Brien J, Lowery K, Perry R, Ince P (1997) A detailed phenomenological comparison of complex visual hallucinations in dementia with Lewy bodies and Alzheimer's disease. *Int Psychogeriatr* 9:381-388.
15. Ballard C, O'Brien J, Swann AG, Thompson P, Neill D, McKeith IG (2001) The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistence and new cases over 1 year of follow-up. *J Clin Psychiatry* 62:45-49.

16. Barcelo-Coblijn G, Hogyes E, Kitajka K, Puskas LG, Zvara A, Hackler L, Nyakas C, Penke Z, Farkas T. Modification by docosahexaenoic acid of age-induced alterations in gene expression and molecular composition of rat brain phospholipids. *Proc Natl Acad Sci USA* 2003; 100:11321-6.
17. Beal MF (1995) Aging, energy and oxidative stress in neurodegenerative diseases. *Ann Neurol* 38:357-66.
18. Benjamin R, Leake A, Ince PG, Perry RH, McKeith IG, Edwarson JA, Morris CM (1995) Effects of apolipoprotein E genotype on cortical neuropathology in senile dementia of the Lewy body and Alzheimer's disease. *Neurodegeneration* 4:443-448.
19. Berlett BS, Stadtman ER (1997) Protein oxidation in aging, disease, and oxidative stress *J Biol Chem.* 1997 Aug 15;272(33):20313-6.
20. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. *Nat Neurosci* Dec; 3(12):1301-6.
21. Bezard E, Gross CE, Fournier MC, Dovero S, Bloch B, Jaber M (1999) Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. *Exp Neurol* 155:268-273.
22. Bielski BH, Arudi RL, Sutherland MW (1983) *J Biol Chem.* Apr 25;258(8):4759-61.
23. Biere AL, Wood SJ, Wypych J, Steavenson S, Jiang Y, Anafi D, Jacobsen FW, Jarosinski MA, Wu GM, Louis JC, Martin F, Narhi LO, Citron M. (2000) Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs. *J Biol Chem.* Nov 3;275(44):34574-9.
24. Blum D, Torch N, Lambeng Nissou M, Benabid AL, Sadoul R, Verna JM, (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease *Prog Neurobiol* 65 135-172.
25. Böhm D, Schwegler H, Kotthaus L, Nayernia K, Rickmann M, Köhler M, Rosenbusch J, Engel W, Flügge G, Burfeind P (2002) Disruption of PLCβ1-mediated signal transduction in mutant mice causes age-dependent hippocampal mossy fiber sprouting and neurodegeneration. *Mol Cell Neurosci* 21: 584-601.
26. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibañez P, Joesse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. *Science* 299:256-259.
27. Boyle E, McGeer P (1990) Cellular immune response in multiple sclerosis plaques. *Am J Pathol* 137, 575-584.
28. Braak E, Sandman-Keil D, Rub U, Gai WP, de Vos RA, Steur EN, Arai K, Braak H (2001) alpha-synuclein immunopositive Parkinson's disease inclusion bodies in lower brain stem nuclei. *Acta Neuropathol* 101:195-201.
29. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. *Acta Neuropath* 82: 239-259
30. Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J, Jellinger K (1994) Amygdala pathology in Parkinson's disease. *Acta Neuropathol* 88:493-500.
31. Braak, H., D. Sandmann-Keil, et al. (1999). Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry." *Neurosci Lett* **265**(1): 67-9.
32. Bradley SR, Marino MJ, Wittmann M, Rouse ST, Awad H, Levey AI, Conn.PJ (2000) Activation of group II metabotropic glutamate receptors inhibit synaptic excitation of the substantia nigra pars reticulata. *J Neurosci* 20: 3085-3094.
33. Brett J, Schmidts AM, Yan SD, Zou YS, Weidman E, Pinski D, Nowygrod R, Neeper M., Przysiecki C, Shaw A (1993) Survey of the distribution of a newly

- characterized receptor for advanced glycation end products in tissues. *Am J Pathol* ; 143:1699-12.
34. Breyse N, Baunez C, Spooren W, Gasparini F, Amalric M (2002) Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. *J Neurosci* 22: 5669-5678.
 35. Buchman VL, Adu J, Pinon LG, Ninkina NN, Davies AM. (1998) Persyn, a member of the synuclein family, influences neurofilament network integrity. *Nat Neurosci.* Jun;1(2):101-3.
 36. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, Lu B, Nussbaum RL. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. *J Neurosci* Oct 15; 22(20):8797-807.
 37. Calderon J, Perry RJ, Erzinclioglu SW, Berrios GE, Denning TR, Hodges JR (2001) Perception, alteration and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 70: 157-164.
 38. Campbell BC, Li QX, Culvenor JG, Jakala P, Cappai R, Beyreuther K, Masters CL, McLean CA (2000) Accumulation of insoluble alpha-synuclein in dementia with Lewy bodies. *Neurobiol Dis* 7:192-200.
 39. Castegna A, Aksenov M, Aksonova M, Thongbookerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Buttefield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. *Free Rad Biol Med* 33:562-71
 40. Castellani R, Smith MA, Richey PL, Perry G (1996) Glycooxidation and oxidative stress in Parkinson's disease and Diffuse Lewy Body disease. *Brain Res* 737: 195-200.
 41. Cechi C, Fiorillo C, Sorbi S, Latorraca S, Nacmias B, Bagnoli S, Nassi P, Liguri G. Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients. *Free Radic Biol Med* 2002;33:1372-9.
 42. Chandra S, Chen X, Rizo J, Jahn R, Sudhof TC. (2003) A broken alpha-helix in folded alpha-Synuclein. *J Biol Chem.* Apr 25;278(17):15313-8. Epub 2003 Feb 13.
 43. Chase TN, Oh JD (2000) Striatal mechanism and pathogenesis of parkinsonian signs and motor complications. *Ann Neurol* 47:S122-129; discussion S129-130.
 44. Chen YG, Siddhanta A, Austin CD, Hammond SM, Sung TC, Frohman MA, Morris AJ, Shields D (1997) Phospholipase D stimulates release of nascent secretory vesicles from the trans-Golgi network. *J Cell Biol* 138, 495-504.
 45. Chiba K, Trevor A, Castagnoli N Jr (1984). Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. *Biochem Biophys Res Commun* 120:574-578.
 46. Chung KKK, Dawson VL, Dawson TM (2001) The role of ubiquitin-proteosomal pathway in Parkinson's disease and other neurodegenerative disorders. *TINS* Nov;24 (11 Suppl):S7-14.
 47. Chung SH, Takai Y, Holz RW (1995) Evidence that the rab3a-binding protein, rabphilin 3a, enhances regulated secretion. *Studies in adrenal chromaffin cells.* *J Biol Chem* 270, 16714-16719.
 48. Ciliax BJ, Drash GW, Staley JK, Haber S, Mobley CJ, Miller GW, Mufson DC, Levey AI (1999) Immunocytochemical localization of the dopamine transporter in human brain. *J Comp Neurol* 409:38-56
 49. Clayton DF, George JM (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. *J Neurosci Res* Oct 1; 58(1):120-9.
 50. Clayton DF, George JM. (1998) The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. *Trends Neurosci* Jun 21(6):249-54.

51. Colley WC, Sung TC, Roll R, Jenco J, Hammond SM, Altshuler Y, Bar-Sagi D, Morris AJ, Frohman MA (1997) Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization. *Curr Biol* 7:191-192.
52. Conn P, Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. *Ann Rev Pharmacol Toxicol* 37: 205-237.
53. Cowburn RF, O'Neill C, Bonkale WL, Ohm TG, Fatbom J (2001) Receptor-G-protein signalling in Alzheimer's disease. *Biochem Soc Symp* 67: 163-175.
54. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. *Proc Natl Acad Sci USA.*;101:2070-5.
55. Dalfo E, Gomez-Isla T, Rosa JL, Nieto Bodelon M, Cuadrado Tejedor M, Barrachina M, Ambrosio S, Ferrer I (2004) Abnormal alpha-synuclein interactions with Rab proteins in alpha-synuclein A30P transgenic mice. *J Neuropathol Exp Neurol Apr*; 63(4):302-13.
56. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. *Brain* 122:1437-1448
57. D'Andrea, M. R., S. Ilyin, et al. (2001) Abnormal patterns of microtubule-associated protein-2 (MAP-2) immunolabeling in neuronal nuclei and Lewy bodies in Parkinson's disease substantia nigra brain tissues. *Neurosci Lett* **306**(3): 137-40.
58. Davidson WS, Jonas A, Clayton DF, George JM (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. *J Biol Chem Apr* 17; 273(16):9443-9.
59. de Silva HR, Khan NL, Wood NW (2000) The genetics of Parkinson's disease. *Curr Opin Genet Dev Jun*10 (3):292-8.
60. de Vos RA, Jansen EN, Stam FC, Ravid R, Swaab DF (1995) "Lewy body disease": clinico-pathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia. *Clin Neurol Neurosurg* 97:13-22.
61. Deane R, Du Yan S, Subramanian RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. *Nat Med.*9:907-13.
62. Den Hartog Jager W, Bethlem J (1960) The distribution of Lewy bodies in the central and autonomic nervous system in idiopathic paralysis agitans. *J Neurol Neurosurg Psychiatry* 23:283-290.
63. DeStefano AL, Lew MF, Golbe LI, Mark MH, Lazzarini AM, Guttman M, Montgomery E, Waters CH, Singer C, Watts RL, Currie LJ, Wooten GF (2002) PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. *Am. J. Hum. Genet.* 70: 1089-1095.
64. Dev KK, Hofele K, Barbieri S, Buchman VL, van der Putten H. (2003) Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. *Neuropharmacology Jul*; 45(1):14-44.
65. Dewar D, Chalmers DT, Graham DI, McCulloch J (1991) Glutamate metabotropic and AMPA binding sites are reduced in Alzheimer's disease: An autoradiographic study of the hippocampus. *Brain Res* 553: 58-64.
66. Dexter DT, Carter C, Agid F (1986) Lipid peroxidation as a cause of nigral death in Parkinson's disease. *Lancet* 2: 639-640.
67. Dexter DT, Holley AE, Flitter WD, Slatter TF, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD. (1994) Increased levels of lipid hydroperoxides in Parkinsonian substantia nigra: an HPLC and ESR study. *Mov Disord* 9:92-7.

68. Dexter DT, Jenner P, Schapira AHV, Marsden CD (1992) Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. *Ann Neurol* 32:S94-S100.
69. Dexter DT, Wells Fr, Lees AJ, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. *J Neurochem* 52:1830-6.
70. Dickson D, Lee S, Mattiace L, Yen S, Brosnan C (1993) Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. *Glia* 7, 75-83.
71. Dickson DW, Davies P, Mayeux R, Crystal H, Horoupian DS, Thompson A, Goldman JE (1987) Diffuse Lewy body disease. Neuropathological and biochemical studies of six patients. *Acta Neuropathol* 75:8-15.
72. Dickson DW, Liu W, Hardy J, Farrer M, Mehta N, Uitti R, Mark M, Zimmerman T, Golbe L, Sage J, Sima A, D'Amato C, Albin R, Gilman S, Yen SH. (1999) Widespread alterations of alpha-synuclein in multiple system atrophy. *Am J Pathol* 155:1241-1251.
73. Ding TT, Lee SJ, Rochet JC, Lansbury PT Jr. (2002) Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. *Biochemistry* 41(32): 10209-17.
74. Downing, DT, Lazo ND (1999) Molecular modelling indicates that the pathological conformations of prion proteins might be beta-helical. *Biochem J* 343:453-460.
75. Duda J. E., Giasson B. I., Chen Q. et al. (2000a) Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. *Am. J. Pathol.* 157, 1439-1445.
76. Duda J. E., Giasson B. I., Gur T. L. et al. (2000b) Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. *J. Neuropathol. Exp. Neurol.* 59, 830-841.
77. Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ. (2002) Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. *Ann Neurol* Aug; 52(2):205-10.
78. Duda JE, Lee VM, Trojanowski JQ (2000) Neuropathology of synuclein aggregates. *J Neurosci Res* 61:121-127.
79. Duffy PE, Tennyson VM (1965) Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus coeruleus in Parkinson's disease. *J Neuropathol Exp Neurol* 24:398-414.
80. Duyckaerts C, Dickson DW (2003) Neuropathology of Alzheimer's disease. In: Dickson D (ed.) *Neurodegeneration: The molecular pathology of dementia and movement disorders*. ISN Neuropathol Press, Basel, pp. 47-68
81. Ebadi M, Govitrapong S, Sharma D, Muralikrishnan S, Shavali L, Pellett R, Schafer C, Albanco J, Eken J (2001) Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of Parkinson's disease. *Biol Signals Recept.* 10: 224-253.
82. el-Agnaf OM, Irvine GB. (2002) Aggregation and neurotoxicity of alpha-synuclein and related peptides. *Biochem Soc Trans.* Aug;30(4):559-65.
83. El-Agnaf OM, Irvine GB. Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins. (2000) *J Struct Biol.* Jun;130(2-3):300-9.
84. El-Agnaf OM, Jakes R, Curran MD, Middleton D, Ingenito R, Bianchi E, Pessi A, Neill D, Wallace A. (1998) Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments *FEBS Lett.* Nov 27;440(1-2):71-5.
85. El-Agnaf OM, Jakes R, Curran MD, Wallace A (1998) Effects of the mutation Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. *FEBS Lett* 1998; 440:67-70.

86. Eliezer D, Kutluay E, Bussell R Jr, Browne G. (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. *J Mol Biol* Apr 6;307(4):1061-73
87. Ellis CE, Schwartzberg PL, Grider TL, Fink DW, Nussbaum RL (2001) Alpha-synuclein is phosphorylated by members of the Src family of protein tyrosine kinases. *J Biol Chem* 276, 3879-3884.
88. Engelender S, Kaminsky Z, Guo X, Sharp AH, Amaravi RK, Kleiderlein JJ, Margolis RL, Troncoso JC, Lanahan AA, Worley PF, Dawson VL, Dawson TM, Ross CA. (1999) Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. *Nat Genet.* May;22(1):110-4.
89. Fabunmi RP, Wigley WC, Thomas PJ, DeMartino GN (2000) Activity and regulation of the centrosome-associated proteasome. *J Biol Chem* 275, 409-413.
90. Farooqui AA, Horrocks LA (2001) Plasmalogens, phospholipase A(2), and docosahexaenoic acid turnover in brain tissue. *J Mol Neurosci* 264-72
91. Farrer M, Gwinn-Hardy K, Muentner M, DeVrieze FW, Crook R, Perez-Tur J, Lincoln S, Maraganore D, Alder C, Newman S, MacElwee K, McCarthy P, Miller C, Waters C, Hardy J (1999) A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. *Hum Mol Genet* 8:81-85.
92. Farrer M, Wavrant-De Vrieze F, Crook R, Boles L, Perez-Tur J, Hardy J, Johnson WG, Steele J, Maraganore D, Gwinn K, Lynch T. Low frequency of alpha-synuclein mutations in familial Parkinson's disease. *Ann Neurol.* 1998 Mar;43(3):394-7.
93. Favreliere S, Perault MC, Huget F, De Javel D, Bertrand M, Piriou A, Durand G. (2003) DHA-enriched phospholipids diets modulate age-related alterations in rat hippocampus. *Neurobiol Aging.*; 24:233-43.
94. Feany MB, Bender WW. A Drosophila model of Parkinson's disease (2000) *Nature.* Mar 23;404(6776):394-8.
95. Feeley Kearney JA, Albin RL (2003) mGluRs: a target for pharmacotherapy in Parkinson's disease. *Exp Neurol* 184, suppl 1:S30-36.
96. Ferrer I (2002) The Neuropathological spectrum of Lewy Body disorders. En: Neurodegenerative disorders associated with α -synuclein pathology. Eds Tolosa E, Schulz JB, McKeith IG, Ferrer I, *Ars Medica* 83-98.
97. Ferrer I, Blanco R, Carmona M, Puig B, Barrachina M, Gomez C, Ambrosio S. Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies. *J Neural Transm.* 2001;108(12):1383-96.
98. Fischer von Mollard G, Stahl B, Li C, Südhof TC, Jan R (1994) Rab proteins in regulated exocytosis. *Trends Biochem* 19, 164-169.
99. Fischer von Mollard G, Südhof, TC, Jan R (1991) A small GTP-binding protein dissociates from synaptic vesicles during exocytosis. *Nature* 349, 79-81.
100. Floor E, Wetzel MG (1998) Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. *J Neurochem* 70: 268-275
101. Forno LS, Sternberger L, Sternberger N, Strefling A, Swanson K, Eng L (1986) Reaction of Lewy bodies with antibodies to phosphorylated and non-phosphorylated neurofilaments. *Neurosci Lett* 64:253-8
102. French BA, van Leeuwen F, Riley NE, Yuan QX, Bardag-Gorce F, Gaal K, Lue, YH, Marceau N, French SW (2001) Aggresome formation in liver cells in response to different toxic mechanisms: role of the ubiquitin-proteasome pathway and the frameshift mutant of ubiquitin. *Exp Mol Pathol* 71, 241-246.
103. Fujiwara H (2002) α -synuclein is phosphorylated in synucleinopathy lesions. *Nat Cell Biol* 4:160-164.
104. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg S, Shen J, Takio K, Iwatsubo T (2002) α -Synuclein is phosphorylated in synucleinopathy lesions. *Nat Cell Biol* 4:160-164.

105. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji , Obata F (2002) A new locus for Parkinson's diseases (PARK8) maps to chromosome 12p11.2-q13.1 *Ann Neurol* 51:296-301.
106. Galindo MF, Jordan J, Gonzalez-Garcia C, Ceña, V (2003) Chromaffin cell death induced by 6-hydroxidopamine is independent of mitochondrial swelling and caspase activation. *J Neurochem* 84 1066-1073.
107. Galloway PH, Sahgal A, McKeith IG (1992) Visual pattern recognition memeory and learning deficits in senile dementias of Alzheimer and Lewy body types. *Dementia* 3:101-107.
108. Gallyas F. Silver staining of Alzheimer's neurofibrillary changes by means of physical development (1971) *Acta Morphol Acad Sci Hung.*;19(1):1-8.
109. Galvin JE, Lee VM-Y, Trojanowski JQ (2001) Synucleinopathies: Clinical and pathologic implications. *Arch Neurol* Feb;58(2):186-90, Review.
110. Gasser T, Muller-Myhsok B, Wszolek ZK, Oehlmann R, Calne DB, Bonifati V, Bereznoi B, Fabrizio E, Vieregge P, Horstmann RD (1998) A susceptibility locus for Parkinson's disease maps to chromosome 2p13. *Nat Genet.* Mar;18(3):262-5.
111. George JM, Jin H, Woods WS, Clayton DF. (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. *Neuron* Aug;15(2):361-72.
112. Geppert M, Bolshakov VY, Siegelbaum SA, Takei K, De Camilli P, Hammer RE, Südhof TC (1994) The role of Rab3A in neurotransmitter release. *Nature* 369, 493-497.
113. Geppert M, Goda Y, Stevens CF, Südhof TC (1997) The small GTP-binding protein Rab3A regulates a late step in synaptic vesicle fusion. *Nature* Jun 19; 387(6635):810-4.
114. German DC, Nelson EL, Liang CL, Speciale SG, Sinton CM, Sonsalla PK (1996) The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. *Neurodegeneration* 5: 299-312.
115. Giandomenico AR, Cerniglia GE, Biaglow JE, Stevens C., Koch CJ, (1997) The importance of sodium pyruvate in assessing damage produced by hydrogen peroxide *Free Radic Biol Med* 23: 426-434.
116. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos, H, Trojanowski JQ, Lee VM (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. *Science* 290, 985-989.
117. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. *Neuron* May 16; 34(4):521-33.
118. Giasson BI, Galvin JE, Lee VM, Trojanowski JQ (2000) Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. *Am J Pathol* Aug; 157(2):361-8.
119. Giasson BI, Jakes R, Goedert M, Duda JE, Leight S, Trojanowski JQ, Lee VM. (2000) A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. *J Neurosci Res* Feb 15; 59(4):528-33.
120. Giasson BI, Lee VM (2000) A new link between pesticides and Parkinson's disease. *Nat Neurosci* Dec 3(12):1227-8.
121. Giasson BI, Uryu K, Trojanowski JQ, Lee VM (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. *J Biol Chem.* Mar 19;274(12):7619-22.
122. gibb WR, Esiri MM, Lees Aj (1987) Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia) *Brain* 110, 1131-1153.
123. Goedert M (1997) Familial Parkinson's disease. The awakening of alpha-synuclein. *Nature* Jul 17; 388 (6639):232-3.

124. Goedert, M. (1999) Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies." *Philos Trans R Soc Lond B Biol Sci* **354**(1386): 1101-18.
125. Gomez-Isla T, Irizarry MC, Mariash A, Cheung B, Soto O, Schrupp S, Sondel J, Kotilinek L, Day J, Schwarzschild MA, Cha JH, Newell K, Miller DW, Ueda K, Young AB, Hyman BT, Ashe KH (2003) Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. *Neurobiol Aging* Mar-Apr; 24(2):245-58.
126. Gomez-Tortosa E, Irizarry MC, Gomez-Isla T, Hyman BT.(2000) Clinical and neuropathological correlates of dementia with Lewy bodies *Ann N Y Acad Sci* 920:9-15.
127. Gomez-Tortosa E, Newell K, Irizarri MC, Sanders JL, Hyman BT (2000) alpha-synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. *Acta Neuropathol* 99: 352-357.
128. Good PF, Hsu A, Werner P, Perl DP, Olanow CW (1998) Protein nitration in Parkinson's disease. *J Neuropathol Exp Neurol* 57, 338-342.
129. Greemayer JT, Mackenzie G, Peng TI, Stephans SE (1999) Mitochondrial dysfunction in Parkinson's disease. *Biochem Soc Symp* 66:85-97.
130. Grimsby J, Toth M, Chen K, Kumazawa T, Klaidman L, Adams JD, Karoum F, Gal J (1997) Increased stress response and beta-phenylethylamine in MAOB deficient mice. *Nat Genet* 17:206-210.
131. Gu M, Gash T, Cooper JM, Wenning GK, Daniel SE, Quinn NP, Marsden CD, Schapira AH (1997) Mitochondrial respiratory chain function in multiple system atrophy. *Mov disord* 12:418-422.
132. Gwinn-Hardy K, Mehta ND, Farrer M, Maraganore D, Muentner M, Yen SH, Hardy J, Dickson DW (2000) Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. *Acta Neuropath.* 99: 663-672.
133. Hamilton RL (2000) Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. *Brain Pathol* 10:378-384.
134. Hamm HE (1998)The many faces of G protein signaling. *J Biol Chem* 273: 669-672.
135. Hammond C (2003) Cellular and Molecular Neurobiology. Chapter 14: The metabotropic glutamate receptors, pp. 314-326, Academic Press: Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney, Tokyo.
136. Hampshire DJ, Roberts E, Crown Y, Bond J, Mibaidin A, Wriekat AL, Al-Din A, Woods CG. Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36. (2001) *J Med Genet* 38:680-682.
137. Han H, Weinreb PH, Lansbury PT Jr (1995) The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid *Chem Biol Mar*;2(3):163-9
138. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, Thal L, Pay MM, Hofstetter R, Klauber M i col (1990) The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. *Neurology* 40:1-8.
139. Hansen LA (1997) The Lewy body variant of Alzheimer's disease. *J Neural Transm Suppl* 51:83-93.
140. Hansen LA, Daniel SE, Wilcock GK, Love S (1998) Frontal cortical synaptophysin in Lewy body diseases:relation to Alzheimer's disease and dementia. *J Neurol Neurosurg Psychiatry* 64:653-656.
141. Harper JD, Wong SS, Lieber CM, Lansbury PT Jr. (1999) Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. *Biochemistry.* Jul 13;38(28):8972-80.

142. Harrington CR, Louwagie J, Rossau R, Vanmechelen E, Perry RH, Perry EK, Xuereb JH, Roth M, Wischik CM (1994) Senile dementia of Lewy bodt type and Alzheimer type are biochemically distinct in terms of paired helical filaments and hyperphosphorylated tau protein. *Dementia* 5:215-228.
143. Hartman A, Hirsch EC (2001) Parkinson's disease. The apoptosis hypothesis revisited. *Adv Neurol* 86: 143-153.
144. Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee VM, Trojanowski JQ, Mann D, Iwatsubo T (2002) Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. *J Biol Chem* 277(50):49071-6. Epub 2002 Oct 10.
145. Hashimoto M, Hsu LJ, Sisk A, Xia Y, Takeda A, Sundsmo M, Masliah E. (1998) Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. *Brain Res* Jul 20; 799(2):301-6.
146. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, Masliah E. (1999) Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. *Neuroreport* 10:717-21.
147. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, Masliah E. (1999) Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. *Neuroreport* Mar 17; 10(4):717-21.
148. Hashimoto M, Masliah E (1999) Alpha-synuclein in Lewy body disease and Alzheimer's disease. *Brain Pathol* Oct; 9(4):707-20.
149. Hashimoto M, Masliah E (2003) Cycles of aberrant synaptic sprouting and neurodegeneration in Alzheimer's and dementia with Lewy bodies. *Neurochem Res* Nov 28(11):1743-56.
150. Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E (2001) beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. *Neuron* Oct 25; 32(2):213-23.
151. Hashimoto M, Rockenstein E, Masliah E. (2003) Transgenic models of alpha-synuclein pathology: past, present, and future. *Ann N Y Acad Sci* Jun 991:171-88.
152. Hashimoto M, Takeda A, Hsu LJ, Takenouchi T, Masliah E (1999) Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. *J Biol Chem* Oct 8; 274(41):28849-52.
153. Hashimoto M, Yoshimoto M, Sisk A, Hsu LJ, Sundsmo M, Kittel A, Saitoh T, Miller A, Masliah E. (1997) NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation. *Biochem Biophys Res Commun* Aug 28; 237(3):611-6.
154. Heintz N, Zoghbi H (1997) α -synuclein--a link between Parkinson and Alzheimer diseases? *Nature Genet.* **16**, 325-327.
155. Hicks AA, Petursson H, Jonsson T, Stefansson H, Johannsdottir HS, Sainz J, Frigge ML, Kong A, Gulcher JR, Stefansson K, Sveinbjornsdottir S (2002) A susceptibility gene for late-onset idiopathic Parkinson's disease. *Ann Neurol* 52:549-555.
156. Higuchi, S., H. Arai, et al. (1998) Mutation in the alpha-synuclein gene and sporadic Parkinson's disease, Alzheimer's disease, and dementia with lewy bodies. *Exp Neurol* 153(1): 164-6.
157. Hishikawa N, Hashizume Y, Yoshida M, Sobue G. (2001) Widespread occurrence of argyrophilic glial inclusions in Parkinson's disease. *Neuropathol Appl Neurobiol* ; 27: 362-372.
158. Ho, S. L. and M. H. Kung (1998) G209A mutation in the alpha-synuclein gene is rare and not associated with sporadic Parkinson's disease. *Mov Disord* 13(6): 970-1.
159. Hoffner G, Kahlem P, Djian P (2002) Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease. *J Cell Sci* 115, 941-948.

160. Hölscher C (1998) Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis. *Neurobiol Dis* 5:129-141.
161. Howells DW, Porritt MJ, Wong JY, Batchelor PE, Kalnins R, Hughes AJ, Donnan GA (2000) Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. *Exp Neurol* 166:127-135
162. Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, Wong J, Takenouchi T, Hashimoto M, Masliah E (2000) alpha-synuclein promotes mitochondrial deficit and oxidative stress. *Am J Pathol* Aug; 157(2):401-10.
163. Hu CJ, Sung SM, Liu HC, Chang JG (1999) No mutation of G209A in the alpha-synuclein gene in sporadic Parkinson's disease among Taiwan Chinese. *Eur. Neurol.* 41, 85-87.
164. Ii K, Ito H, Tanaka K, Hirano A (1997) Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. *J Neuropathol Exp Neurol* 56: 125-131.
165. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R (2001) An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. *Cell* 105:891-902.
166. Ince PG, McKeith I (2002) Dementia with Lewy bodies. *A Neurodegeneration The molecular pathologies of dementia and movement disorders*. DW Dennis (eds). ISN Neuropath Press: Basel
167. Ince PG, Perry EK, Morris CM (1998) Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome? *Brain Pathol* 8:299-324.
168. Iranzo A, Santamaria J, Tolosa E (2000) Continuous positive air pressure eliminates nocturnal stridor in multiple system atrophy. Barcelona multiple System Atrophy Study Group. *Lancet* 356:1329-1330.
169. Irizarry MC, Growdon W, Gomez-Isla T, Newell K, George JM, Clayton DF, Hyman BT (1998) Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. *J Neuropathol Exp Neurol* Apr; 57(4):334-7.
170. Irizarry MC, Kim TW, McNamara M, Tanzi RE, George JM, Clayton DF, Hyman BT (1996) Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system. *J Neuropathol Exp Neurol* Aug; 55(8):889-95.
171. Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin JC, Smith CD, Beckman JS (1992) Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. *Arch biochem Biophys* 298:431-7.
172. Iseki E, Marui W, Kosaka K *et al.* Degenerative terminals of the perforant pathway are human alpha-synuclein immunoreactive in the hippocampus of patients with diffuse Lewy body disease. *Neurosci Lett* 1998; **258**: 81-84.
173. Iseki E, Mauri W, Akiyama H, Ueda K, Kosaka K (2000) Degeneration process of Lewy bodies in the brains of patients with dementia with Lewy bodies using alpha-synuclein immunohistochemistry. *Neurosci Lett* 286:69-73.
174. Ishikawa A, Takahashi H, Tanaka H, Hayashi T, Tsuji S (1997) Clinical features of familial diffuse Lewy body disease. *Eur Neurol* 38:34-38.
175. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H. A. R., Kittel A., and Saitoh T. (1995a) The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. *Neuron* 14, 467-475.
176. Iwatsubo T (2003) Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease. *J Neurol* 250 suppl 3: 11-14.
177. Jähn R, Südhof TC (1994) Synaptic vesicles and exocytosis. *Annu. Rev. Neurosci* 17, 219-246.
178. Jakes R, Spillantini MG, Goedert M (1994) Identification of two distinct synucleins from human brain. *FEBS Lett.* May 23; 345 (1):27-32.

179. Jellinger K (2003) Neuropathological spectrum of synucleinopathies. *Mov Disord Suppl* 6: S2-12.
180. Jellinger KA (2001b) Cell death mechanisms in neurodegeneration. *J. Cell Mol Med* 5:1-7
181. Jellinger KA (2002) Recent developments in the pathology of Parkinson's disease. *J Neural Transm Suppl* (62): 347-376.
182. Jellinger KA i Mizuno Y (2003) Parkinson's disease In: *Neurodegeneration: The Molecular Pathology of Dementia and movement Disorders* Ed: Dickson D. ISN Neuropath Press
183. Jenner P (1991) Oxidative stress as a cause of Parkinson's disease. *Acta Neurol Scand* 84: 6-15.
184. Jenner P (1998) Oxidative mechanisms in nigral cell death in Parkinson's disease. *Mov Disord* 13:24-34.
185. Jensen PH, Hager H, Nielsen MS, Hojrup P, Gliemann J ,Jakes R (1999) α -Synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. *J. Biol. Chem.* 274, 25481-25489.
186. Jensen PH, Nielsen MS, Jakes R, Dotti CG, Goedert M (1998) Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. *J Biol Chem* Oct 9; 273(41):26292-4.
187. Jensen PH, WP Gai (2001) Alpha-synuclein. Axonal transport, ligand interaction and neurodegeneration." *Adv Exp Med Biol* 487: 129-34.
188. Ji H, Liu YE, Jia T, Wang M, Liu J, Xiao G, Joseph BK, Rosen C, Shi YE (1997) Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. *Cancer Res* 1997; 57: 759-764
189. Jo E, Darabie AA, Han K, Tandon A, Fraser PE, McLaurin J (2000) alpha-Synuclein membrane interactions and lipid specificity. *J Biol Chem* 275(44): 34328-34.
190. Johnston JA, Ward CL, Kopito RR (1998) Aggresomes: a cellular response to misfolded proteins. *J. Cell Biol* 143, 1883-1898.
191. Kahle PJ, Neumann M, Ozmen L, Muller V, Odoy S, Okamoto N, Jacobsen H, Iwatsubo T, Trojanowski JQ, Takahashi H, Wakabayashi K, Bogdanovic N, Riederer P, Kretschmar HA, Haass C (2001) Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. *Am J Pathol* Dec; 159 (6):2215-25.
192. Kakimura J, Kitamura Y, Takata K, Kohno Y, Nomura Y, Taniguchi T (2001) Release and aggregation of cytochrome C and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. *Eur J Pharmacol* 417:59-67.
193. Kang j, Lemaire HG, Unterbeck a, salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B (1987) the precursor of alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. *Nature* 325, 733-736.
194. Kang J, Muller-hill, b (1990) differential splicing of alzheimer's disease amyloid A4 precursor RNA in rat tissues: PreA4(695) mRNA is predominantly produced in rat and human brain. *Biochem. Biophys Res commun* 166, 1192-1200.
195. Katzman R, Galasko D, Saitoh T, Thal LJ, Hansen L (1995) Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. *Brain Cogn* 28:259-265.
196. Kaul M, Garden G, Lipton S (2001) Pathways to neuronal injury and apoptosis in HIV-associated dementia. *Nature* 410, 988-994.
197. Kawanishi C, Suzuki K, Odawara T, Iseki E, Onishi H, Miyakawa T, Yamada Y, Kosaka K, Kondo N, Yamamoto T (1996) Neuropathological evaluation and apolipoprotein E gene polymorphism analysis in diffuse Lewy body disease. *J Neurol Sci* 136:140-142.

198. Kessler M, Terramani T, Lynch G, Baudry M (1989) A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonist. *J Neurochem* 52: 1319-28.
199. Kim D, Jun KS, Lee SB, Kang NG, Min DS, Kim YH, Ryu SH, Suh PG, Shin SH (1997) Phospholipase C isozymes selectively couple to specific neurotransmitter receptors. *Nature* 389: 290-293.
200. Kim, T. D., H. J. Ryu, et al. (2000) Thermal behavior of proteins: heat-resistant proteins and their heat-induced secondary structural changes." *Biochemistry* 39(48): 14839-46.
201. Kimelberg HK, Pang S, Treble DH (1989) Excitatory amino acid-stimulated uptake of $^{22}\text{Na}^+$ in primary astrocyte cultures. *J Neurosci* 9: 1141-9.
202. Kimura T, Takamatsu J, Miyata T, Miyakawa T, Horiuchi S (1998) Localization of identified advanced glycation end-products structures, N^ε (carboxymethyl)lysine and pentosidine in age-related inclusions in human brains. *Pathol Int*; 48:575-9.
203. Kitaguchi N, Takahashi Y, Tokushima Y, Shiojiri S, Ito H (1988) Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity. *Nature* 331, 530-532.
204. Klatka LA, Louis ED, Schiffer RB (1996) Psychiatric features in diffuse Lewy body disease: a clinico-pathologic study using Alzheimer's disease and Parkinson's disease comparison groups. *Neurology* 47:1148-1152.
205. Kolakowski LF (1994) GCRDb: a G-protein-coupled receptor database. *Receptor Channels* 2:1-7.
206. Kong CK, Yim MB, Stadman ER, Chock PB (1996) Peroxynitrite disables the tyrosine phosphorylation regulatory mechanisms: lymphocyte-specific tyrosine kinase fails to phosphorylate nitrated cdc (6-20) NH₂ peptide. *Proc Natl Acad Sci USA* 93:3377-82.
207. Kopito RR (2000) Aggresomes, inclusion bodies and protein aggregation. *Trends Cell Biol* 10, 524-530.
208. Kosaka K (1978) Lewy bodies in cerebral cortex. Report of three cases. *Acta Neuropathol* 42:127-134
209. Kosaka K, Iseki E (1996) Diffuse Lewy body disease within the spectrum of Lewy body disease. In *Dementia with Lewy Bodies*, RH Perry, IG McKeith., EK Perry (eds.) Cambridge University Press: Cambridge. Pp. 238-247.
210. Kowall NW, Hantraye P, Brouillet E, Beal MF, McKee AC, Ferrante RJ (2000) MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. *Neuroreport* 11:211-213.
211. Kreutzberg W (1996) Microglia: a sensor for pathological events in the CNS. *Trends Neurosci* 19, 312-318.
212. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Eppelen JT, Schols L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. *Nat Genet.* Feb;18(2):106-8
213. Kubo SI, Kitami T, Noda S, Shimura H, Uchiyama Y, Asakawa S, Minoshima S, Shimizu N, Mizuno Y, Hattori N (2001) Parkin is associated with cellular vesicles. *J Neurochem* 78:42-54.
214. Kumlesh KD, Katja H, Barbieri S, Buchman VL, van der Putten H (2003) Part II: α -synuclein and its molecular pathophysiological role in neurodegenerative disease. *Neuropharmacology* 45:14-44.
215. Kuzuhara S, Mori H, Izumiyama N, Yoshimura M, Ihara Y (1988) Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. *Acta Neuropathol (Berl)*75(4):345-53.
216. Lamb H, Christie J, Singleton AB, Leake A, Perry RH, Ince PG, McKeith IG, Melton LM, Edwarson JA, Morris CM (1998) Apolipoprotein E and alpha-1 antichymotripsin polymorphism genotyping in Alzheimer's disease and in dementia with Lewy bodies. Distinctions between diseases. *Neurology* 50:388-391.

217. Lang AE, Lozano AM (1998a) Parkinson's disease. First of two parts. *N Engl J Med* 339:1044-1053.
218. Lang AE, Lozano AM (1998b) Parkinson's disease. Second of two parts. *N Engl J Med* 339:1130-1143. 26.
219. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. *Science* 219:979-980.
220. Lantos PL (1998) The definition of multiple system atrophy: a review of recent developments. *J Neuropathol Exp Neurol* 57: 1099-1111.
221. Lantos PL, Quinn N (2003) Multiple system atrophy. In: Dickson D (edit) *Neurodegeneration: The molecular pathology of dementia and movement disorders*, ISN Neuropath Press, Basel, pp 203-213.
222. Larsen CN, Krantz BA, Wilkinson KD (1998) Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. *Biochemistry*. Mar 10;37(10):3358-68.
223. Lavedan C, Leroy E, Dehejia A, Buchholtz S, Dutra A, Nussbaum RL, Polymeropoulos MH (1998) Identification, localization and characterization of the human gamma-synuclein gene. *Hum Genet*. Jul;103(1):106-12.
224. Law SW, Conneely OM, DeMayo FJ, (1992) *et al.* Identification of a new brain-specific transcription factor, NURR1. *Mol Endocrinol*;6:2129-35.
225. Le W, Conneely OM, Zou L, *et al.* (1999) Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. *Exp Neurol* 159:451-8
226. Lee M, Hyun D, Halliwell B, Jenner P (2001) Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. *J Neurochem* 76:998-1009.
227. Lee MK Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, Price DL (2002) Human alpha-synuclein harbouring familial Parkinson's disease-linked Ala53-Thr mutations causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. *Proc. Natl Acad Sci USA* 99:8968-8973.
228. Lee RK, Jimenez J, Cox AJ, Wurtman RJ (1996) Metabotropic glutamate receptors regulate APP processing in hippocampal neurons and cortical astrocytes derived from fetal rats. *Ann NY Acad Sci* 777: 338-343.
229. Lee SR, Kim AR, Kim JS, Kim J, Lee JY, Lee YL, Choe M, Park JB (2001) The proteins of synaptic vesicle membranes are affected during ageing of rat brain. *Exp Mol Med* Dec 31; 33(4):220-5.
230. Lee VMY, Trojanowski JQ, Buée L, Christen Y (2000) *Fatal attractions: protein aggregates in neurodegenerative disorders*. Springer, Berlin, Heidelberg, New York, Barcelona, Hong Kong, London, Milan, Paris, Singapore, Tokyo.
231. Lee Y, Nagai AJ, Kim S (2002) Cytokines, chemokines and cytokine receptors in human microglia. *J Neurosci Res* 69, 94-103.
232. Leigh PN, Probst A, Dale GE, Power DP, Brion JP, Dodson A, Anderton BH (1989) New aspects of the pathology of neurodegenerative disorders as revealed by ubiquitin antibodies. *Acta Neuropathol (Berl)* 79:61-72
233. Lennox GG, Lowe JS. (1998) Dementia with Lewy bodies. In: Markersberry, WR, editor. *Neuropathology of dementing disorders*. London, New York, Sydney, Auckland: Arnold; p.181-92.
234. Leroy, E.; Boyer, R.; Auburger, G.; Leube, B.; Ulm, G.; Mezey, E.; Harta, G.; Brownstein, M. J.; Jonnalagada, S.; Chernova, T.; Dehejia, A.; Lavedan, C.; Gasser, T.; Steinbach, P. J.; Wilkinson, K. D.; Polymeropoulos, M. H. The ubiquitin pathway in Parkinson's disease. (Letter) *Nature* 395: 451-452, 1998.
235. Lewy FH. Paralysis agitans. In: Lewandowsky M, ed. *Pathologische Anatomie. Handbuch der Neurologie*. Berlin: Springer-Verlag, 1912;920-933.

236. Li L, Ohman T, Deeb SS, Fukuchi KI (1999) Analysis of mouse intron 7 DNA sequence of the APP gene: comparison with the human homologue. *DNA Seq* 10, 219-228.
237. Li C, Takei K, Geppert M, Daniell L, Stenius K, Chapman ER, Jahn R, De Camilli P, Südhof TC (1994) Synaptic targeting of rabphilin-3A, a synaptic vesicle Ca²⁺/phospholipid-binding protein, depends on Rab3A/C. *Neuron* 13, 885-898.
238. Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, Nee LE, O'Connell B, Pollen DA, St George-Hyslop P, Ghetti B, Nochlin D, Bird TD, Cairns NJ, Lee VM, Iwatsubo T, Trojanowski JQ (1998) Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. *Am J Pathol* 153:1365-1370.
239. Lippa CF, Schmidt ML, Lee VM-Y, Trojanowski JQ (1999) Antibodies to α -synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's Disease. *Ann Neurol*; 45: 353-357.
240. Lippa CF, Smith TW, Saunders AM, Crook R, Pulaski-Salo D, Davies P, Hardy J, Roses AD, Dickson D (1995) Apolipoprotein E genotype and Lewy body disease. *Neurology* 45 : 97-103.
241. Lippa CF, Smith TW, Swearer JM (1994) Alzheimer's disease and Lewy body disease: a comparative clinicopathological study. *Ann Neurol* 35, 81-88.
242. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT Jr. (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. *Cell* 111:209-218.
243. Lledó PM, Johannes L, Vernier P, Zorec R, Darchen F, Vincent JD, Henry JP, Mason WT (1994) Rab3 proteins: key players in the control of exocytosis. *Trends Neurosci* 17, 426-432.
244. Lotharius J, Brundin P (2002) Impaired dopamine storage resulting from α -synuclein mutations may contribute to the pathogenesis of Parkinson's disease. *Human mol genet* 11(20): 2395-2407.
245. Lotharius J, Brundin P (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and α -synuclein. *Nature Rev* 3:1-11.
246. Louis ED, Klatka LA, Liu Y, Fahn S (1997) Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease. *Neurology* 48:376-380.
247. Lowe J, McDermott H, Landon M, Mayer RJ, Wilkinson KD (1990) Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. *J Pathol* 161: 153-160.
248. Lucking CB, Brice A (2000) Alpha-synuclein and Parkinson's disease. *Cell Mol Life Sci. Dec*;57(13-14):1894-908.
249. Lucotte G, Mercier G, Turpin JC (1998) Lack of mutation G209A in the α -synuclein gene in French patients with familial and sporadic Parkinson's disease [letter]. *J Neurol Neurosurg Psychiatry*;60:948-949.
250. Lue L, Rydel R, Brigham EF, Yang L, Hampek H, Murphy G M, Brachova L, Yan S, Walker DG, Shen Y i col. (2001) Inflammatory repertoire of Alzheimer's disease and non demented elderly microglia *in vitro*. *Glia* 35, 72-79.
251. Luginger E, Seppi K, Litvan I (2000) Associated Alzheimer pathology modifies the natural history of dementia with Lewy bodies (DLB): a clinicopathological study. *Mov Disord* 15, suppl:226.
252. Ma J, Lindquist S (2001) Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation. *Proc Natl Acad Sci USA* 98, 14955-14960.
253. Ma SY, Ciliax BJ, Stebbins G, Jaffar S, Joyce JN, Cochran EJ, Kordower JH, Mash DC, Levey AI, Mufson EJ (1999a) Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra. *J Comp Neurol* 409:25-37

254. Mages HW, Rilke O, Bravo R, Senger G, Kroczeck RA (1994) NOT, a human immediate-early response gene closely related to the steroid/thyroid hormone receptor NAK1/TR3. *Mol Endocrinol* Nov;8(11):1583-91.
255. Mandel S, Grünblatt E, Maor G, Youdim MBR (2002) Early and late genes in MPTP mice model of Parkinson's disease employing cDNA microarray. *Neurochem Res* 27:1231-1242.
256. Maries E., Dass B., Collier T. J., Kordower J. H. and Steece-Collier K. (2003) The role of alpha-synuclein in Parkinson's disease: insights from animal models. *Nat. Rev. Neurosci.* **4**, 727-738.
257. Mark RJ, Pang Z, Geddes JW, Uchida K, Mattson MP (1997) Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. *J Neurosci*;17(3):1046-54
258. Markesbery WR, Mosoni L, Berlett BS, Stadman ER (1996) Oxidative alterations in Alzheimer's disease. *Brain Pathol* 9:133-1463.
259. Maroteaux L, Campanelli JT, Scheller RH. Maroteaux L, Campanelli JT, Scheller RH. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. *J Neurosci.* Aug;8(8):2804-15.
260. Maroteaux L. and Scheller, R. H. (1991) The rat brain synucleins; family of proteins transiently associated with neuronal membranes. *Mol. Brain Res.* **11**, 335-343.
261. Martin M, Albasanz JL, Fernandez M, Ros M (1998) Cross-talk between beta-adrenergic and metabotropic glutamate receptors in rat C6 glioma cells. *Biochem Biophys Acta* 1393: 186-92.
262. Martin M, Sanz JM, Cubero A (1993) Characterization of metabotropic glutamate receptors coupled to a pertussis toxin sensitive G-protein in bovine brain coated vesicles. *FEBS Let.* 316: 191-6
263. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders *Science* Feb 18;287 (5456):1265-9.
264. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome *Proc. Natl. Acad. Sci. USA* 82, 4245-4249.
265. Matsuoka Y, Vila M, Lincoln S, McCormack A, Picciano M, LaFrancois J, Yu X, Dickson D, Langston WJ, McGowan E, Farrer M, Hardy J, Duff K, Przedborski S, Di Monte DA (2001). Lack of nigral pathology in transgenic mice expressing human a-synuclein driven by the tyrosine hydroxylase promoter. *Neurobiology of Disease*, 8: 535-539
266. McGeer P, Kawamata T, Walker D, Akiyama H, Tooyama I, McGeer E (1993) Microglia in degenerative neurological disease. *Glia* 7, 84-92.
267. McKeith IG, Ballard CG, Perry RH, Ince PG, O'Brien JT, Neill D, Lowery K, Jaros E, Barber R, Thompson P, Swann A, Fairbairn AF, Perry EK (2000) Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. *Neurology* 54: 1050-1058.
268. McKeith IG, Fairbairn AF, Perry RH, Thompson P (1994) The clinical diagnosis and misdiagnosis
269. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwarson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB):report of the consortium on DLB international workshop. *Neurology* 47:113-1124.
270. McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK (1992) Operational criteria for senile dementia of Lewy body type (SDLT). *Psychol Med* 22:911-922.

271. McShane R, Gedling K, Reading M, McDonald B, Esiri MM, Hope T (1995) Prospective study of relations between cortical Lewy bodies, poor eyesight and hallucinations in Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 59:185-188.
272. Meredith GE, Totterdell S, Petroske E, Santa Cruz K, Callison RC Jr, Lau YS. (2002) Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. *Brain Res.* 2002 Nov 22;956(1):156-65
273. Michaelis EK (1998) Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. *Progr Neurobiol* 54: 369-415.
274. Miller GW, Staley JK, Heilman CJ, Pérez JT, Mash DC, Rye DB, Levey AL (1997) Immunochemical analysis of dopamine transporter protein in Parkinson's disease. *Ann Neurol* 41:530-539
275. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, Van Belle G, Berg L. (1991) The Consortium to establish a Registry for Alzheimer's disease (CERAD), part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology*; 41:479-86.
276. Mitsumoto A, Nakagawa Y, Takeuchi A et al (2001) Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat. *Free Radic Res* 35:301-310
277. Miyata, T. , R. Inagi , Y. Iida , M. Sato , N. Yamada , O. Oda , K. Maeda , and H. Seo (1994) Involvement of β_2 -microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. *J. Clin. Invest.* 93: 521-528
278. Moir RD, Lynch t, Bush AI, Whyte S, Henry A, Portbury S, Multhaup G, Small DH, Tanzi RE, Beyreuther K, Masters CL (1988) Relative increase in Alzheimer's disease of soluble forms of cerebral Abeta amyloid protein precursor containing the Kunitz protease inhibitory domain. *J Biol Chem* 273, 5013-5019.
279. Mori F, Tanji K, Yoshimoto M, Takahashi H, Wakabayashi K (2002) Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment. *Exp Neurol* 176:98-104.
280. Morris HR, Vaughan JR, Datta SR, Bandopadhyay R, Rohan De Silva, HA, Schrag A, Cairns NJ, Burn D, Nath U, Lantos PL, Daniel S, Lee AJ, Quinn NP, Wood NW (2000) Multiple system atrophy/progressive supranuclear palsy: α -synuclein, tau and APO E. *Neurology* 55:1918-1920
281. Mruthinti S, Buccafusco JJ, Hill WD, Waller JL, Jackson TW, Zamrini EY, Schade RF. (2004) Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Ab and RAGE peptides. *Neurobiol Aging*, en prensa.
282. Munch G, Luth HJ, Wong A, Arendt T, Hirsch E, Ravid R, Riederer P. *J Chem Neuroanat.* 2000 Dec;20(3-4):253-7.
283. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM (2000) γ -Synucleins are developmentally expressed, and (-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. *J Neurosci* 20:3214-20.
284. Nakajo S, Tsukada K, Omata K, Nakamura Y, Nakaya K (1993) A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation. *Eur J Biochem* 217, 1057-1063.
285. Nakajo, S., Omata, K., Aiuchi, T., Shibayama, T., Okahashi, I., Ochiai, H., Nakai, Y., Nakaya, K., and Nakamura, Y. (1990) Purification and characterization of a novel brain-specific 14 kDa protein. *J. Neurochem.* 55, 2031-2038.
286. Nakamura T, Yamashita H, Takahashi T, Nakamura S (2001) Activated Fyn phosphorylates (-synuclein at tyrosine 125. *Biochem Biophys Res Commun* 280, 1085-1092.
287. Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, Kaufman SA, Martin F, Sitney K, Denis P, Louis JC, Wypych J, Biere AL, Citron M (1999) Both familial

- Parkinson's disease mutations accelerate alpha-synuclein aggregation. *J Biol Chem* 274(14): 9843-6.
288. Negro A, Brunati AM, Donella-Deana A, Massimino ML, Pinna LA (2001) Multiple phosphorylation of α -synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation; *FASEB J.* 2002 Feb;16(2):210-2).
 289. Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooen W, Muller V, Odoy S, Fujiwara H, Hasegawa M, Iwatsubo T, Trojanowski JQ, Kretzschmar HA, Haass C (2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. *J Clin Invest Nov*; 110(10):1429-39.
 290. Neystat M, Lynch T, Przedborski S, Kholodilov N, Rzhetskaya M, Burke R (1999) α -Synuclein expression in substantia nigra and cortex in Parkinson's disease. *Mov Disord* 14:417-422
 291. Nicotra A, Parvez SH (2000) Cell death induced by MPTP, a substrate for monoamino oxidase B. *Toxicology* 153:157-166.
 292. Ninkina, NN, Alimova-Kost, MV, Paterson, JW, Delaney, L, Cohen, BB, Imreh, S, Gnuchev, NV, Davies, AM, & Buchman, VL (1998) Organization, expression and polymorphism of the human persyn gene. *Hum Mol Genet* 7:1417-1424
Chromosomal mapping of the γ -synuclein gene
 293. Nishie M, Mori F, Fujiwara H, Hasegawa M, Yoshimoto M, Iwatsubo T, Takahashi H, Wakabayashi K (2004) Accumulation of phosphorylated synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. *Acta Neuropathol Apr*;107(4):292-8. Epub 2004 Jan 14.
 294. Nonet ML, Stauton JE, Kilgard MP, Fergestad T, Hartweg E, Horvitz HR, Jorgensen EM, Meyer BJ (1997) *Caenorhabditis elegans* rab-3 mutant synapses exhibit impaired function and are partially depleted of vesicles. *J. Neurosci.* 17, 8061-8063.
 295. Ohshima H, Friesen M, Brouet I, Bartsch H (1990) Nitrotyrosine as a new marker for endogenous nitrosation and nitration of proteins. *Food Chem Toxicol*; 28:647-52.
 296. Okochi M, Walter J, Koyama A, Nakajo S, Baba M, Iwatsubo T, Meijer L, Kahle PJ, Haass C (2000) Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein *J Biol Chem* Jan 7;275(1):390-7.
 297. Okochi M, Walter J, Koyama A, Nakajo S, Baba M, Iwatsubo T, Meijer L, Kahle PJ, Haass C (2002) Constitutive phosphorylation of the Parkinson's disease associated α -synuclein. *J Biol Chem* 275:390-397.
 298. Olanow CW (1993) A radical hypothesis for neurodegeneration. *Trends Neurosci*;16:439-44.
 299. Olanow CW, Jenner P, Tatton NA, Tatton WG. (1998) Neurodegeneration and Parkinson's disease. In: Jankovic J, Tolosa E eds. *Parkinson's disease and movement disorders*. Baltimore: Williams & Wilkins :67-103.
 300. Olichney JM, Hansen LA, Galasko D, Saitoh T, Hofstetter CR, Katzman R, Thal LJ (1996) The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. *Neurology* 47:190-196.
 301. Ossowska K, Wardas J, Pietraszek M, Konieczny J, Wolfarth S (2003) The striatopallidal pathway is involved in antiparkinsonian-like effects of the blockade of group I metabotropic glutamate receptors in rats. *Neurosci Lett* 342: 21-2.
 302. Ostermeier C, Brunger AT (1999) Structural basis of Rab effector specificity: crystal structure of the small G protein Rab3A complexed with the effector domain of rabphilin-3A, *Cell* 96, 363-374 .
 303. Ozawa S, Kamiya H, Tsuzuki K (1998) Glutamate receptors in the mammalian central nervous system. *Progr Neurobiol* 54: 518-618.
 304. Ozawa T, Takano H, Onodera O, Kobayashi H, Ikeichi T, Koide R, Okuizumi K, Shimohata T, Wakabayashi K, Takahashi H, Tsuji S (1999) No mutation in the

- entire coding region of the alpha-synuclein gene in pathological confirmed cases of multiple system atrophy. *Neurosci Lett* 270:110-112.
305. Palmer AM (1999) The activity of the pentose phosphate pathway is increased in response to oxidative stress in Alzheimer's disease. *J Neural Transm*; 106:317-28.
 306. Papp MI, Kahn JE, Lantos PL (1989) Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy Drager syndrome). *J Neurol Sci*;94:79-100
 307. Papp MI, Lantos PL (1992) Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy. *J Neurol Sci*;107:172-82
 308. Park IH, Yeon SI, Youn JH, Choi JE, Sasaki N, Choi IH, Shin JS (2004) Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. *Mol Immunol*; 40:1203-11.
 309. Park JB, Kim JS, Lee JY, Kim J, Seo JY, Kim AR (2002) GTP binds to Rab3A in a complex with Ca²⁺/calmodulin. *Biochem J* Mar 15;362 (Pt 3):651-7.
 310. Park, Y. G., Nesterova, M., Agrawal, S., Cho-Chung, Y. S. (1999). Dual Blockade of Cyclic AMP Response Element- (CRE) and AP-1-directed Transcription by CRE-transcription Factor Decoy Oligonucleotide. Gene-specific inhibition of tumor growth. *J. Biol. Chem.* 274: 1573-1580
 311. Parkinson J (1817) An essay on the shaking palsy. Wittingham and Rowald for Sherwood, Neely and Jones: London.
 312. Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, Rueter SM, Trojanowski JQ, Lee VM, Ischiropoulos H (2001) Induction of alpha-synuclein aggregation by intracellular nitrative insult : *J Neurosci.* Oct 15;21(20):8053-61.
 313. Payton JE, Perrin RJ, Clayton DF, George JM (2001) Protein-protein interactions of alpha-synuclein in brain homogenates and transfected cells. *Brain Res Mol Brain Res.* Nov 1;95 (1-2):138-45.
 314. Pennathur S, Jackson-Lewis V, Przedborski S, Heinecke JW (1999) Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o'-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. *J Biol Chem* 274:34621-8.
 315. Pérez Sánchez F, Milán M, Fariñas I (2002) Animal models of α -synucleinopathies. En: *Neurodegenerative disorders associated with α -synuclein pathology.* Eds:Tolosa E, Schulz JB, McKeith IG, Ferrer I. *Ars Medica*, Barcelona, Spain.
 316. Perrin RJ, Woods WS, Clayton DF, George JM. (2001) Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. *J Biol Chem* Nov 9;276(45):41958-62. Epub 2001 Sep 11.
 317. Perutz MF, Pope BJ, Owen D, Wanker EE, Scherzinger E (2002) Aggregation of proteins with expanded glutamine and alanine repeats of the glutamine-rich and asparagine-rich domains of Sup35 and of the amyloid beta-peptide of amyloid plaques." *Proc Natl Acad Sci U S A* 99(8): 5596-600.
 318. Pfeffer SR (1994) Rab GTPases: master regulators of membrane trafficking. *Curr. Opin. Cell Biol.* 6, 522-526.
 319. Piao YS, Hayashi S, Wakabayashi K, Kakita A, Aida I, Yamada M, Takahashi H. (2002) Cerebellar cortical tau pathology in progressive supranuclear palsy and corticobasal degeneration. *Acta Neuropathol (Berl).* May;103(5):469-74. Epub 2002 Jan 25.
 320. Piao YS, Wakabayashi K, Hayashi S, Yoshimoto M, Takahashi H. (2000). Aggregation of alpha-synuclein/NACP in the neuronal and glial cells in diffuse Lewy body disease: a survey of six patients. *Clin Neuropathol* 19(4): 163-9.
 321. Pin JP, Acher F (2002) The metabotropic glutamate receptors: structure, activation, mechanisms and pharmacology. *Curr Drug Target CNS Neural Disord* 1: 297-317.

322. Pisani A, Bonsi P, Centonze D, Gubellini P, Bernardi G, Calabresi P (2003) Targeting striatal cholinergic interneurons in parkinson's disease. Focus on metabotropic glutamate receptors. *Neuropharmacol* 45: 45-56.
323. Plazzi G, Corsini R, Provini F, Pierangeli G, Martinelli P, Montagna P, Lugaresi E, Cortelli P (1997) REM sleep behaviour disorders in multiple system atrophy. *Neurol* 48:1094-1097.
324. Poleev A, Hartman A, Stamm S (2000) A trans-acting factor, isolated by the three-hybrid system, that influences alternative splicing of the amyloid precursor protein minigene. *Eur J Biochem* 267, 4002-4010.
325. Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, Sanges G, Stenroos ES, Pho LT, Schaffeer AA, Lazzarini AM, Nussbaum RL, Duvoisin RC (1996) Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. (see comments) *Science* 274:1197-1199.
326. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer r, Stenroos Es, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, DiIorio G, Golbe L, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science* 276:2045-2047.
327. Ponte P, Gonzalez-DeWhitt P, Schilling J, Miller J, Hsu D, Greenberg b, Davis K, Wallace W, Lieberburg I, Fuller F (1988) a new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. *Nature* 331, 525-527.
328. Pronin AN, Morris AJ, Surguchov A, Benovic JL (2000) Synucleins are a novel class of substrates for G-protein-coupled receptor kinases. *J. Biol Chem*; 275:26515-22.
329. Przedborski S, Chen Q, Vila M, Giasson BI, Djaldatti R, Vukosavic s, souza JM, Jackson-Lewis V, Lee VM, Ischiropoulos H (2001) Oxidative post-trasnlational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. *J Neurochem*;76:637-40.
330. Przedborski S, Jackson-Lewis V (2000) ROS and Parkinson's disease: aview to a kill. In:Poli G, Cadenas E, Packer L, editors. *Free radicals in brain patophysiology*. New York: Marcel Dekker; 200 p 273-90.
331. Przedborski S, Kostic V, Jackson-Lewis V, Naini AB, Simonetti S, Fahn S, Crlnson E, Epstein CJ, Cadet JL (1992) Transgenic mice with increased Cu/Zn-superoxide disnutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropiridine-induced neurotoxicity. *J Neurosci* 12:1658-67.
332. Rapoport SI, Chang MCJ, Spector AA (2001) Delivery and turnover of plasma-derived essential PUFAs in mammalian brain. *J Lip Res*;42:678-85.
333. Rathke-Hartlieb S, Kahle PJ, Neumann M, Ozmen L, Haid S, Okochi M, Haass C, Schulz JB (2001). Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant a-synuclein transgenic mice. *J Neurochemistry*, 77: 1181-1184
334. Rebecchi MJ, Pentylala SN (2000) Structure, function, and control of phosphoinositide-specific phospholipase C. *Physiol Rev* 80: 1291-1335.
335. Rhee SG (2001) Regulation of phosphoinositide-specific phospholipase C. *Annu Rev Biochem* 70: 281-312.
336. Riederer P, Sofic E, Rausch W, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1988) Transition metals ferritin glutathione and ascorbic acid in Parkinsonian brains. *J Neurochem* 52:515-20.
337. Robins TW, James M, Lange KW, Owen AM, Quinn NP, Marsden CD (1992) Cognitive performance in multiple system atrophy. *Brain* 115:271-291.
338. Roy S, Wolman L (1969) Ultrastructural observations in Parkinsonism. *J Pathol. Sep*;99(1):39-44
339. Sahgal A, Galloway PH, McKeith IG, Edwarson JA, Lloyd S (1992) A comparative study of attentional deficits in senile dementias of Alzheimer and Lewy body types. *Dementia* 3:350-354.

340. Sahgal A, Galloway PH, McKeith IG, Lloyd S, Cook JH, Ferrier IN, Edwarson JA (1992) Matching-to-sample deficits in patients with senile dementias of the Alzheimer and Lewy body types. *Arch Neurol* 49:1043-1046.
341. Sahgal A, McKeith IG, Galloway PH, Tasker N, Steckler T (1995) Do differences in visuospatial ability between senile dementias of the Alzheimer and Lewy body types reflect differences solely in mnemonic function? *J Clin Exp Neuropsychol* 17:35-43.
342. Salmon DP, Galasko D, Hansen LA, Masliah E, Butters N, Thal TJ, Katzman R (1996) Neuropsychological deficits associated with diffuse Lewy body disease. *Brain Cogn* 31:148-165.
343. Sasaki N, Toki S, Chowei H, Saito T, Nakano N, Hayashi Y, Takeuchi M, Makita Z (2001). Immunohistochemical distribution of the receptor for advanced glycation end product in neurons and astrocytes in Alzheimer's disease. *Brain Res* 888:256-62.
344. Saucedo-Cardenas O, Quintana-Hau JD, Le WD, (1998) *et al.* Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. *Proc Natl Acad Sci U S A* **95**:4013-18
345. Scearce LM, Laz TM, Hazel TG, et al. (1993) RNR-1, a nuclear receptor in the NGFI-B/Nur77 family that is rapidly induced in regenerating liver. *J Biol Chem*;268:8855-61
346. Schapira AH (1994) Evidence for mitochondrial dysfunction in Parkinson's disease: acritical appraisal. *Mov Disord* 1994; 9:125-38.
347. Schapira AH (2001) Causes of neuronal death in Parkinson's disease. *Adv Neurol* 86:155-162.
348. Schluter OM, Khvotchev M, Jahn R, Sudhof TC (2002) Localization versus function of Rab3 proteins. Evidence for a common regulatory role in controlling fusion. *J Biol Chem*. Oct 25; 277(43):40919-29. Epub 2002 Aug 06.
349. Schluter OM, Schnell E, Verhage M, Tzonopoulos T, Nicoll RA, Janz R, Malenka RC, Geppert M, Sudhof TC (1999) Rabphilin knock-out mice reveal that rabphilin is not required for rab3 function in regulating neurotransmitter release. *J Neurosci*. Jul 15; 19(14):5834-46.
350. Schmidt AM, Yan SD, Wautier JL, Stern DM (1999) Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. *Circ Res*; 84: 489-497.
351. Schmidt AM, Yan SD, Yan SF, Stern DM (2000) The biology of the receptor for advanced glycation end products and its ligands. *Biochim Biophys Acta*; 1498:99-111.
352. Schmidt AM, Yan SD, Yan SF, Stern DM (2000) The biology of the receptor for advanced glycation end products and its ligands. *Biochim. Biophys. Acta* 1498 pp. 99-111.
353. Schmidt AM, Yan SD, Yan SF, Stern DM (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory response. *J Clin Invest* 108 pp. 949-955.
354. Schmidt N, Ferger B (2001) Neurochemical findings in the MPTP model of Parkinson's disease. *J Neural Transm* 108:895-1009
355. Schulz JB, Beal MF (1994) Mitochondrial dysfunction in movement disorders. *Curr Opin Neurol*; 7:333-9.
356. Schulz JB, Dichgans J (1999) Molecular pathogenesis of movement disorders: are protein aggregates a common link in neuronal degeneration? *Curr Opin Neurol*; 12:433-9.
357. Schulz JB, Matthews RT, Muqit MMK, Browne SE, Beal MF (1995) Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. *J Neurochem*; 64:936-9.

358. Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathi YV, Anantharamaiah GM (1992) The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. *J Lipid Res.* Feb;33(2):141-66.
359. Selkoe DJ, Podlisny MB, Joachim CL, vickers EA, Lee G, Fritz LC, Oltersdorf T (1988) Beta-amyloid precursor of Alzheimer's disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and non-neural tissues. *Proc Natl Acad Sci USA* 85, 7341-7345.
360. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA (2000). Fibre diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. *Proc. Natl. Acad. Sci USA* 97, 4897-4902
361. Serrando, M., Casanovas, A. & Esquerda, JE (2002) Occurrence of glutamate receptor subunit 1-containing aggresome-like structures during normal development of rat spinal cord interneurons. *J Comp Neurol*, 442, 23-34.
362. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ (2003) The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. *Neuron.* Feb 20;37(4):583-95.
363. Sharon R, Bar-Joseph I, Mirick GE, Serhan CN, Selkoe DJ. (2003) Altered fatty acid composition of dopaminergic neurons expressing α -synuclein and human brains with α -synucleinopathy. *J Biol Chem* 278: 49874-498781.
364. Sharon R, Goldberg MS, Bar-Josef I, Betensky RA, Shen J, Selkoe DJ (2001) Alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins *Proc Natl Acad Sci U S A.*; Jul 31;98(16):9110-5.
365. Shastry BS (2001) Parkinson's disease: etiology, pathogenesis and future of gene therapy. *Nurosci Res* 41:5-12
366. Shelley ML (1998) 4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. *Free Radic Biol Med* 25: 169-174
367. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT (2002) An *in vitro* model of Parkinson's disease: linking mitochondrial impairment to altered α -synuclein metabolism and oxidative damage. *J Neurosci* 22:7006-7015.
368. Sherere TH, Kim JH, Betarbet R, Greenmayer JT (2002) Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α -synuclein aggregation *Exp Neurol* 179:9-16.
369. Sherman MY, Goldberg AL (2001) Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. *Neuron* 29, 15-32.
370. Shibayama-Imazu T, Okahashi I, Omata K, Nakajo S, Ochiai H, Nakai Y, Hama T, Nakamura Y, Nakaya, K (1993) Cell and tissue distribution and developmental change of neuron specific 14 kDa protein (phosphoneuroprotein 14). *Brain Res.* 622, 17-25.
371. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka KM, Suzuki T(2000) Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. *Nat Genet* 25:302-305.
372. Shimura H, Hattori N, Kubo S, Yoshikawa M, Kitada T, Matsumine H, Asakawa S, Minoshima S, Yamamura Y, Shimizu N, Mizuno Y (1999) Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. *Ann Neurol* 45:668-672.
373. Shirataki H, Yamamoto T, Hagi S, Miura H, Oishi H, Jin-no Y, Senbonmatsu T, Takai Y (1994) Rabphilin-3a is associated with synaptic vesicles in a manner independent of Rab3a. *J. Biol. Chem.* 269, 32717-32720.
374. Simons K, Zerial M (1993) Rab proteins and the road maps for intracellular transport. *Neuron* 11, 789-799.

375. Smith MC, Mallory M, Hansen LA, Ge N, Masliah E (1995) Fragmentation of the neuronal cytoskeleton in the Lewy body variant of Alzheimer's disease. *Neuroreport* 6: 673-679.
376. Smith Y, Charara A, Hanson JE, Paquet M, Levey AI (2000) GABA (B) and group I metabotropic glutamate receptors in the striatopallidal complex in primates. *J Anat* 196: 555-57669.
377. Soderberg M, Edlund C, Krisstensson K, Dallner G (1991) Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. *Lipids*;26:421-5.
378. Souza JM, Giasson BI, Lee VM, Ischiropoulos H (2000) Chaperone-like activity of synucleins. *FEBS Lett.* May 26;474(1):116-9.
379. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. *Neurosci Lett.* Jul 31; 251(3):205-8.
380. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. *Proc Natl Acad Sci U S A.* May 26; 95(11):6469-73.
381. Spillantini MG, Divane A, Goedert M (1995) Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35. *Genomics.* May 20; 27(2):379-81.
382. Spillantini MG, Goedert M (2000)The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. *Ann N Y Acad Sci*; 920:16-27.
383. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. *Nature* Aug 28; 388(6645):839-40.
384. Staal RG, Sonsalla PK (2000) Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. *J Pharmacol Exp Ther* 293:336-342.
385. Stoll G, Jander S (1999) The role of microglia and microphages in the pathophysiology of the CNS. *Prog Neurobiol* 58, 233-247.
386. Südhof, T.C. (1997) Function of Rab3 GTP-GDP exchange. *Neuron* 18, 519-522.
387. Sung JY, Kim J, Paik SR, Park JH, Ahn YS, Chung KC (2001) Induction of neuronal death by Rab5A-dependent endocytosis of synuclein. *J Biol Chem*;276:27441-27448.
388. Surguchov A, Surgucheva I, Solessio E., Baehr W (1999) Synoretin - a new protein belonging to the synuclein family. *Mol Cell Neurosc*, 13, 95-103.
389. Tabrizi SJ, Orth M, Wilkinson JM, Taanman JW, Warner TT, Cooper JM, Schapira AH. (2000) Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity *Hum Mol Genet.* Nov 1;9(18):2683-9.
390. Takahashi T, Yamashita H, Nagano Y, Nakamura T, Ohmori H, Avraham H, Avraham S, Yasuda M, Matsumoto M (2003) Identification and characterization of a novel Pyk2/related adhesion focal tyrosine kinase-associated protein that inhibits alpha-synuclein phosphorylation *J Biol Chem.* Oct 24;278(43):42225-33. Epub 2003 Jul 31.
391. Takahashi T, Yamashita H, Nakamura T, Nagano Y, Nakamura S. (2002) Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrate stress *Brain Res.* May 31;938(1-2):73-80.
392. Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Masliah E. (2000) C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders. *Acta Neuropathol (Berl).* Mar; 99(3):296-304.
393. Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Sisk A, Masliah E (1998) Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment *Lab Invest.* Sep;78(9):1169-77.

394. Tanaka Y, Engelender S, Igarashi s, Rao RK, Wanner T, Rudolph ET, Sawa A, Dawson VL, Dawson TM, Ross CA (2001) Inducible expression of mutant α -synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. *Human Mol Gen* 10 (9):919-926.
395. Tanzi RE, McClathchey AI, Lamperti ED, Villa-Komaroff L, Gusella JF, Neve RL (1988) Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease. *Nature* 331, 528-530.
396. Terada S, Ishizu H, Haraguchi T, Takehisha Y, Tanabe Y, Kawai K, Kuroda S (2000) Tau-negative astrocytic star-like inclusions and coiled bodies in dementia with Lewy bodies. *Acta Neuropathol* 100:464-468.
The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. *Science* 246: 670-673.
397. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. *Biochem J.* 1999;344:109-16.
398. Tobe T, Nakajo S, Tanaka A, Mitoya A, Omata K, Nakaya K, Tomita M, Nakamura Y (1992) Cloning and characterization of the cDNA encoding a novel brain specific 14-kDa protein. *J. Neurochem.* 59, 1624-1629.
399. Togo T, Iseki E, Marui W, Akiyama H, Ueda K, Kosaka K(2001) Glial involvement in the degeneration process of Lewy body-bearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies. *J Neurol Sci.* Feb 15;184(1):71-5.
400. Trojanowski JQ, Goedert M, Iwatsubo T, Lee VM (1998) Fattal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia *Cell Death Differ Oct; 5(10):832-7.*
401. Trojanowski JQ, Lee VM (1998) Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. *Ann Neurol Sep; 44(3):415-22.*
402. Trojanowski JQ, Lee VM (2002) Parkinson's disease and related synucleinopathies are a new class of nervous system amyloidoses. *Neurotoxicology Oct; 23(4-5):457-60.*
403. Trotti D, Rossi D, Gjesdal O, Levy LM, Racagni G, Danbolt NC, Volterra A (1996) Peroxynitrite inhibits glutamate transporter subtypes. *J Biol Chem; 271:5976-9.*
404. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DAC, Kondo J, Ihara Y, Saitoh T (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. *Proc. Natl. Acad. Sci. USA* 90, 11282-11286.
405. Uryu K, Giasson BI, Longhi L, Martinez D, Murray I, Conte V, Nakamura M, Saatman K, Talbot K, Horiguchi T, McIntosh T, Lee VM, Trojanowski JQ (2003) Age-dependent synuclein pathology following traumatic brain injury in mice. *Exp Neurol Nov 184 (1):214-24.*
406. Uversky VN, Li J, Fink AL (2001) Pesticides directly accelerate the rate of alpha-synuclein fibril-formation: a possible factor in Parkinson's disease. *FEBS Lett* 500:105-108.
407. Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, Ialongo T, Frontali M, Albanese A, Wood NW (2001) Localization of a novel locus for autosomal recessive early-onset parkinsonism PARK6, on human chromosome 1p35-p36. *Am J Hum Genet* 68:895-900.
408. Valenti O, Marino MJ, Wittmann M, Lis E, DiLella AG, Kinnery GG, Conn PJ (2003) Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. *J Neurosci* 23: 7218-7226.
409. Van der Putten H, Wiederhold KH, Probst A, Barbieri S, Mistl C, Danner S, Kauffmann S, Hofele K, Spooren WPJM, Ruegg MA, Lin S, Caroni P, Sommer B, Tolnay M, Bilbe G (2000) Neuropathology in mice expressing human a-synuclein. *Journal of Neuroscience; 20 (16): 6021-6029.*

410. van Duijin CM, Drekker MC, Bonifati V, Galjaard RJ, Houwing-Duistermaat JJ, Snijders PJ, Testers L, Breedveld GJ, Horstink M, Sandkuijl LA, van Swieten JC, Oostra BA, Heutink P (2001) PARK7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. *Am J Hum Genet* 69:629-634.
411. Van Muiswinkel FL, Raupp SF, de Vos NM., Smits HA., Verhoef J, Eikelenboom P, Nottet HS (1999) The amino-terminus of the amyloid-beta protein is critical for the cellular binding and consequent activation of the respiratory burst of human macrophages. *J. Neuroimmunol.* 96:121-130.
412. Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Korsmeyer SJ, Przedborski S (2001) Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. *Proc Natl Acad Sci USA* 98:2837-2842.
413. Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S (2000) Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxic MPTP. *J Neurochem* 74:721-729.
414. Vila M, Wu DC, Przedborski S (2001) Engineered modelling and the secrets of Parkinson's disease. *TINS* 24 (suppl):49-55.
415. Vogel G (1997) Gene discovery offers tentative clues to Parkinson's. *Science.* Jun 27;276(5321):1973.
416. Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H, Wanker EE (2001) Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. *Mol Biol Cell* 12, 1393-1407.
417. Wakabayashi K, Hansen LA, Masliah E (1995) Cortical Lewy body-containing neurons are pyramidal cells: laser confocal imaging of double-immunolabeled sections with anti-ubiquitin and SMI32. *Acta Neuropathol* 89:404-408.
418. Wakabayashi K, Hayashi S, Kakita A, Yamada M, Toyoshima Y, Yoshimoto M, Takahashi H. (1998a) Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. *Acta Neuropathol (Berl)* 96: 445-452.
419. Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. (1998b) Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. *Neurosci Lett* 249: 180-182.
420. Wakabayashi, K., Matsumoto, K., Takayama, K., Yoshimoto, M., and Takahashi, H. (1997) NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. *Neurosci.Lett.* 239, 45-48.
421. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron M M, Lomakin A, Benedek GB, Selkoe DJ, Teplow DB (1999) Amyloid b-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. *J Biol Chem* **274**, 25945-25952
422. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB (1997) Amyloid b-protein fibrillogenesis. Detection of a protofibrillar intermediate. *J Biol Chem* 272, 22364-22372
423. Wang Y, Liu X, Biederer T, Südhof TC (2002) A family of RIM-binding proteins regulated by alternative splicing. Implications for the genesis of synaptic active zones. *Proc Natl Acad Sci USA* 99, 14464-14469.
424. Wenning GK, Geser F, Stampfer-Kountchev M, Tison F (2003) Multiple system atrophy: an update. *Mov Disord Sep; 18 Suppl 6:S34-42.*
425. Wenning GK, Tisson F, Ben Shlomo Y, Daniel SE, Quinn NP (1997) A review of 203 pathologically proven cases. *Mov Disord* 12:133-147.
426. Wigley WC, Fabunmi RP, Lee MG, Marino CR, Muallem S, DeMartino GN, Thomas PJ (1999) Dynamic association of proteasomal machinery with the centrosome. *J Cell Biol* 145, 481-490.
427. Wilkinson KD, Lee K, Deshpande S, Duerksen-Hughes P, Boss J M, Pohl J (1989)

428. Willingham S, Outeiro TF, DeVit MJ, Lindquist SL, Muchowski PJ (2003) Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. *Science*. Dec 5;302(5651):1769-72.
429. Yamaguchi K, Tanaka M, Mizoguchi A, Hirata Y, Ishizaki H, Kaneko K, Miyoshi J, Takai Y. (2002) A GDP/GTP exchange protein for the Rab3 small G protein family up-regulates a postdocking step of synaptic exocytosis in central synapses. *Proc Natl Acad Sci U S A* Oct 29; 99(22):14536-41. Epub Oct 18.
430. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli, Nawroth P, Stern D, Schmidt AM (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. *Nature*; 382:685-691.
431. Yan SD, Chen X, Schmidt AM, Brett J, Goldman G, Zou YS, Scott CW, Caputo C, Frappier T, Smith MA, Perry G, Yen S-H, Stern D (1994) Glycated tau protein in Alzheimer's disease: a mechanism for induction of oxidant stress. *Proc Natl Acad Sci USA*; 91:7787-91.
432. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H (2003) Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. *Biochem J*. 370:1097-109
433. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. *Proc Natl Acad Sci USA* 93: 2696-2701.
434. Yoshikai S, Sasaki H, Doh-ura K, Furuya H, Sakaki Y (1990) Genomic organization of the human amyloid beta-protein precursor gene. *Gene* 87, 257-263.
435. Young RA, Talbot K, Gao ZY, Trojanowski JQ, Wolf BA (1999) Phospholipase pathway in Alzheimer's disease brains: decreased G α_1 in dorsal prefrontal cortex. *Mol Brain Res* 66: 188-190.
436. Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atarés B, Llorens V, Gómez-Tortosa E, del Ser T, Muñoz MD, De Yebens JG (2004) The new mutation, E46K, of (-Synuclein Causes Parkinson and Lewy Body Dementia. *Ann Neurol*; 55:164-173.
437. Zerial M, McBride H (2001) Rab proteins as membrane organizers. *Nat Rev Mol Cell Biol*; 2:107-117.
438. Zetterstrom RH, Solomin L, Jansson L, (1997) et al. Dopamine neuron agenesis in Nurr1-deficient mice. *Science*;276:248-50
439. Zetterstrom RH, Williams R, Perlmann T, (1996) Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. *Brain Res Mol Brain Res*;41:111-20.
440. Zhang J, Dawson VL, Dawson TM (2000) Oxidative stress and genetics in the pathogenesis of Parkinson's disease, *Neurobiol Dis* Aug;7(4): 240-250.
441. Zhang J, Graham DG, Montine TJ, Ho YS (2000) Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase. *J Neuropathol Exp Neurol* 59:53-61.
442. Zhang Y, Gao J, Chung KK, Huang K, Dawson VL, Dawson TM (2000) Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein CDCrel-1. *Proc Natl Acad Sci USA* 97:13354-13359.